Literature DB >> 11864719

Dopamine dysfunction in AD/HD: integrating clinical and basic neuroscience research.

Mary V Solanto1.   

Abstract

There is strong evidence that the catecholamines dopamine and norepinephrine are both important in the pathophysiology of ADHD, as well as in the mechanism of therapeutic action of stimulant drugs. Due to the known effects of stimulants in blocking reuptake of catecholamines and (in the case of D-amphetamine) facilitating their release, it has traditionally been believed that the stimulants compensate for catecholamine deficiency in ADHD. More recently, however, alternate hypotheses of a hyperdopaminergic and/or hyper-noradrenergic state in ADHD have been suggested. This paper will be limited to a review of the evidence for involvement of dopamine in mediating behavioral and cognitive symptoms and response to stimulants in ADHD, with implications for possible mechanisms.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11864719     DOI: 10.1016/s0166-4328(01)00431-4

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  101 in total

Review 1.  Fragile X syndrome and targeted treatment trials.

Authors:  Randi Hagerman; Julie Lauterborn; Jacky Au; Elizabeth Berry-Kravis
Journal:  Results Probl Cell Differ       Date:  2012

Review 2.  Towards conceptualizing a neural systems-based anatomy of attention-deficit/hyperactivity disorder.

Authors:  Nikos Makris; Joseph Biederman; Michael C Monuteaux; Larry J Seidman
Journal:  Dev Neurosci       Date:  2009-04-17       Impact factor: 2.984

3.  Potential contribution of monoamine oxidase a gene variants in ADHD and behavioral co-morbidities: scenario in eastern Indian probands.

Authors:  A Karmakar; S Maitra; D Verma; B Chakraborti; R Goswami; P Ghosh; S Sinha; K P Mohanakumar; R Usha; K Mukhopadhyay
Journal:  Neurochem Res       Date:  2014-03-21       Impact factor: 3.996

4.  The psychopharmacology of impulsive behaviour in rats VIII: effects of amphetamine, methylphenidate, and other drugs on responding maintained by a fixed consecutive number avoidance schedule.

Authors:  John Evenden; Tracey Ko
Journal:  Psychopharmacology (Berl)       Date:  2005-02-17       Impact factor: 4.530

5.  Acute and sub-chronic functional neurotoxicity of methylphenidate on neural networks in vitro.

Authors:  K V Gopal; B R Miller; G W Gross
Journal:  J Neural Transm (Vienna)       Date:  2007-06-18       Impact factor: 3.575

6.  Examination of methylphenidate-mediated behavior regulation by glycogen synthase kinase-3 in mice.

Authors:  Marjelo A Mines; Eleonore Beurel; Richard S Jope
Journal:  Eur J Pharmacol       Date:  2012-10-23       Impact factor: 4.432

7.  Effects of acute nicotine administration on behavioral inhibition in adolescents with attention-deficit/hyperactivity disorder.

Authors:  Alexandra S Potter; Paul A Newhouse
Journal:  Psychopharmacology (Berl)       Date:  2004-04-09       Impact factor: 4.530

8.  Inactivation of the maternal fragile X gene results in sensitization of GABAB receptor function in the offspring.

Authors:  Bojana Zupan; Miklos Toth
Journal:  J Pharmacol Exp Ther       Date:  2008-09-23       Impact factor: 4.030

9.  Neurocognitive effects of methylphenidate in adult attention-deficit/hyperactivity disorder.

Authors:  Danielle C Turner; Andrew D Blackwell; Jonathan H Dowson; Andrew McLean; Barbara J Sahakian
Journal:  Psychopharmacology (Berl)       Date:  2004-08-27       Impact factor: 4.530

10.  Dopamine transporter genotype and stimulant side effect factors in youth diagnosed with attention-deficit/hyperactivity disorder.

Authors:  Reut Gruber; Ridha Joober; Natalie Grizenko; Bennett L Leventhal; Edwin H Cook; Mark A Stein
Journal:  J Child Adolesc Psychopharmacol       Date:  2009-06       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.